Life sciences

Straightforward business-friendly advice from lawyers who understand the unique challenges and opportunities presented by the life sciences sector.  We enjoy spending time getting to know our clients and working alongside them for the long term.
  • Profile
  • Experience
  • Key contacts

We work with a wide range of clients from the life sciences sector including:

  • pharmaceutical companies
  • biotechnology companies
  • medical device and diagnostic companies
  • manufacturers, distributors and logistics companies
  • investors
  • banks and financial institutions.

We work with companies of all sizes, from start-ups to multinational industry leaders. Whether it's a complex matter affecting your entire business or a more routine matter, we have the knowledge and commitment to assist you.

We have particular expertise in:

  • acquisitions and disposals
  • investments and financings
  • IPOs
  • licensing deals
  • collaboration agreements
  • manufacturing, distribution and logistics contracts
  • multi-jurisdictional disputes
  • intellectual property
  • tax structuring
  • competition/anti-trust issues
  • employment, pensions and incentives advice
  • data privacy issues
  • real estate for laboratory and manufacturing facilities, including associated planning and environmental matters.
"High-quality advice, personable solicitors, great individual care and attention. A team who genuinely care and want to make a different to their clients whether to win, negotiate or settle."
The Legal 500 UK 2020

Woodford Investment Management

We advised on the set up and launch of Woodford Patient Capital Trust plc, an innovative investment trust offering exposure to early-stage companies with outstanding intellectual property and long-term return opportunities.

Vernalis plc

We have advised this AIM-listed development stage pharmaceutical company on a number of out-licensing and collaboration deals, including the out-licensing of the worldwide rights to its proprietary adenosine receptor antagonist technology to a US company.


We have advised GSK on a number of trade mark matters including a multi-jurisdictional dispute relating to the colour of its global blockbuster inhaler product, Seretide.

BTG plc

We have advised BTG plc, a FTSE-250 international specialist pharmaceutical company, on a range of M&A, financing and licensing matters including its $220 million acquisition of EKOS Corporation, an International vascular business, headquartered in Seattle, US.

ARIAD Pharmaceuticals

We have assisted this specialist oncology company, headquartered in Cambridge (Massachusetts), with commercial, competition, data protection and employment advice related to its entry into the European market.


We have advised this global biopharma company on a variety of significant and more routine commercial contracts and a dispute with a licensing partner.

Piramal Enterprises

We have advised this Mumbai-listed company on a wide variety of matters, including the sale of its domestic formulations division to Abbot Healthcare for $3.8 billion.

Lansen Pharmaceutical Holdings Limited

We advised Lansen on its acquisition from Novartis AG of the rights to sell Sicorten Plus, a dermatological product, in China.

Eisai Europe Ltd

We have advised this Japanese headquartered pharmaceutical company on confidential employment and HR matters in the UK for many years.


We have advised this Global 500 company on corporate governance, data protection, competition law compliance, and medical advertising in Asia.


Giovanna Kwong Partner

T:  +852 2533 2787
M:  Email Giovanna | Vcard Office:  Hong Kong


Alexandra Pygall Partner

T:  +44 20 7809 2137
M:  +44 7881 314 566 Email Alexandra | Vcard Office:  London

Latest news & insights

28 Jan 2020

From Insights

Documents disclosed to the EMA as part of an MA application process are not presumed to be confidential

On 22 January 2020 the CJEU handed down two decisions in which it decided that the EMA was entitled to disclose to third parties the study reports submitted to it by a..


09 Dec 2019

From News

Stephenson Harwood advises capiton on KD Pharma single-asset secondary

Law firm Stephenson Harwood LLP has advised private equity firm capiton on a general partner-led single asset secondary transaction relating to the KD Pharma Group.


11 Sep 2019

From News

Guillaume Briant joins Stephenson Harwood as partner

Law firm Stephenson Harwood LLP has expanded its corporate practice with the arrival of partner Guillaume Briant, who joins the firm's Paris office.


29 Jan 2019

From News

Alexandra Pygall named in The Lawyer's Hot 100

Stephenson Harwood partner Alexandra Pygall has been named in The Lawyer's Hot 100 - Dealmaker list.


16 Jul 2018

From News

Stephenson Harwood advises on Piramal Imaging sale

Law firm Stephenson Harwood LLP has advised on the sale of Piramal Imaging SA to UK based medical imaging services provider Alliance Medical Group.


04 Jun 2018

From Insights

The EU Export Manufacturing Waiver: A boost for the Generic and Biosimilar Medicines Market?

On 28 May the European Commission adopted a legislative proposal for a regulation to amend Regulation (EC) No. 469/2009 on Supplementary Protection Certificates (SPCs)..


10 Apr 2018

From Insights

Genomic medicine: regulating clinical pathways

Consultant Cliodhna McDonough shares her views on genomic medicine and regulatory issues which require further analysis with Pharma Times.


29 Nov 2017

From News

Stephenson Harwood (Singapore) Alliance advises on Chemopharm sale to Everstone Group

Stephenson Harwood (Singapore) Alliance has advised Malaysia-headquartered Chemopharm Sdn Bhd., a leading pan-Southeast Asia medical devices distribution group, on the..


30 Oct 2017

From News

Cliodhna McDonough joins Stephenson Harwood

Law firm Stephenson Harwood LLP has strengthened its life sciences and consumer practices with the arrival of Cliodhna McDonough, who joins the firm's London office as..


25 Aug 2016

From News

Stephenson Harwood advises Cell Medica on cutting edge research and licence agreements

Law firm Stephenson Harwood LLP has advised Cell Medica Limited on a research collaboration agreement and associated option and licence agreement with University Colle..


25 Feb 2016

From News

Stephenson Harwood advises on £162 million IPO for Shield Therapeutics plc

Stephenson Harwood LLP has advised Shield Therapeutics plc (“Shield”) on its £162 million AIM IPO.


22 May 2014

From News

Stephenson Harwood LLP advises on two AIM reverse takeovers

International law firm Stephenson Harwood LLP has advised on the two recent reverse takeovers of Feedback plc ("Feedback") and Rex Bionics Plc ("Rex Bionics").


© Stephenson Harwood LLP 2016. Any reference to Stephenson Harwood in this document means Stephenson Harwood LLP and/or its affiliated undertakings. Any reference to a partner is used to refer to a member of Stephenson Harwood LLP.